BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

...had raised $5 million via a convertible note from Barer, Rapha, Salem Partners, TEDCO and Piedmont...
BioCentury | Jan 24, 2019
Emerging Company Profile

Caelus' microbes for metabolic syndrome

...University collaborators: Academic Medical Center, Wageningen University and Research Centre, Ghent University, University of Eastern Piedmont...
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology; dermatology

...Med. Chem. ; published online May 3, 2018 doi:10.1021/acs.jmedchem.8b00109 CONTACT: Tracey Pirali, University of Eastern Piedmont...
...CONTACT: Asia Fernández-Carvajal, Miguel Hernández University, Elche, Spain email: asia.fernandez@umh.es Hongjiang Li Miguel Hernandez University University of Eastern Piedmont Transient...
BioCentury | Jan 5, 2018
Financial News

NexImmune raises $23M series A

...co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont...
BioCentury | Jan 2, 2018
Financial News

NexImmune raises $23M series A

...co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Diacylglycerol kinase α (DGKα); SH2 domain containing 1A (SH2D1A); T cell receptor (TCR)

...Sci. Transl. Med.; published online Jan. 13, 2016 doi:10.1126/scitranslmed.aad1565 CONTACT: Andrea Graziani, University of Eastern Piedmont...
BioCentury | Jul 21, 2014
Company News

Piedmont board of directors update

Piedmont Pharmaceuticals LLC , Greensboro, N.C. Business: Infectious, Veterinary Appointed: Dennis Steadman, founder and former CEO of Velcera Inc., which Perrigo Co. plc aquired, as chairman WIR Staff Infectious...
BioCentury | Jun 15, 2009
Financial News

Pique Therapeutics completes venture financing

...Inc. , Durham, N.C. Business: Cancer Date completed: 6/9/09 Type: Venture financing Raised: Undisclosed Investors: Piedmont...
BioCentury | Apr 13, 2009
Company News

Charles River Laboratories Inc., Magen, PPD Inc. deal

...cancer service subsidiary, Piedmont Research Center LLC, for $46 million in cash. Charles River said Piedmont's...
BioCentury | Apr 7, 2008
Company News

Impax management update

...Generics Hired: Michael Nestor as divisional president of Impax's Impax Pharmaceuticals division, formerly COO of Piedmont Pharmaceuticals LLC...
Items per page:
1 - 10 of 13
BioCentury | Jun 24, 2020
Finance

AsclepiX aims for basket of retinal indications with $35M series A

...had raised $5 million via a convertible note from Barer, Rapha, Salem Partners, TEDCO and Piedmont...
BioCentury | Jan 24, 2019
Emerging Company Profile

Caelus' microbes for metabolic syndrome

...University collaborators: Academic Medical Center, Wageningen University and Research Centre, Ghent University, University of Eastern Piedmont...
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology; dermatology

...Med. Chem. ; published online May 3, 2018 doi:10.1021/acs.jmedchem.8b00109 CONTACT: Tracey Pirali, University of Eastern Piedmont...
...CONTACT: Asia Fernández-Carvajal, Miguel Hernández University, Elche, Spain email: asia.fernandez@umh.es Hongjiang Li Miguel Hernandez University University of Eastern Piedmont Transient...
BioCentury | Jan 5, 2018
Financial News

NexImmune raises $23M series A

...co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont...
BioCentury | Jan 2, 2018
Financial News

NexImmune raises $23M series A

...co-led by new investor ArrowMark Partners and existing investor Barer & Son Capital. Existing investor Piedmont...
BioCentury | Mar 3, 2016
Distillery Therapeutics

Therapeutics: Diacylglycerol kinase α (DGKα); SH2 domain containing 1A (SH2D1A); T cell receptor (TCR)

...Sci. Transl. Med.; published online Jan. 13, 2016 doi:10.1126/scitranslmed.aad1565 CONTACT: Andrea Graziani, University of Eastern Piedmont...
BioCentury | Jul 21, 2014
Company News

Piedmont board of directors update

Piedmont Pharmaceuticals LLC , Greensboro, N.C. Business: Infectious, Veterinary Appointed: Dennis Steadman, founder and former CEO of Velcera Inc., which Perrigo Co. plc aquired, as chairman WIR Staff Infectious...
BioCentury | Jun 15, 2009
Financial News

Pique Therapeutics completes venture financing

...Inc. , Durham, N.C. Business: Cancer Date completed: 6/9/09 Type: Venture financing Raised: Undisclosed Investors: Piedmont...
BioCentury | Apr 13, 2009
Company News

Charles River Laboratories Inc., Magen, PPD Inc. deal

...cancer service subsidiary, Piedmont Research Center LLC, for $46 million in cash. Charles River said Piedmont's...
BioCentury | Apr 7, 2008
Company News

Impax management update

...Generics Hired: Michael Nestor as divisional president of Impax's Impax Pharmaceuticals division, formerly COO of Piedmont Pharmaceuticals LLC...
Items per page:
1 - 10 of 13